VCYT
VeracyteBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Sustained adoption of Veracyte’s core genomic tests combined with favorable reimbursement headlines and one or more commercial partnerships could drive above-consensus revenue growth and margin expansion, supporting multiple expansion to reach the bull target within 12 months.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.2.
What can break
Clinical data or regulatory setbacks
Momentum
92
Value
60
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $39.57 · Bull $46.76 · Bear $28.78
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $49.55
Why
Momentum92 · Δ7d +0.2
Value60 · Δ7d -0.0
Sentiment30 · Δ7d -3.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendSoftening
Δ7d
+0.2
Δ21d
+34.0
Value
60
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.3
Sentiment
30
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.1
Δ21d
-10.3
Why this grade
Composite grade B. Momentum 92.2 / Value 60.1 / Sentiment 29.7
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$3.81B
Beta
1.91
Shares Out
79.05M
P/E (TTM)
115.1
P/S (TTM)
6.97
P/FCF (TTM)
35.12
Rev YoY
+13.8%
EPS YoY
+24.3%
Gross Margin
+68.5%
Op Margin
+5.0%
Net Debt
-$289.44M
Current Ratio
6.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology